Malgorzata E. Smas

TL;DR: A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.

TL;DR: A high-throughput microfluidic mixing device, the herringbone-chip, or “HB-Chip,” is described, which provides an enhanced platform for CTC isolation and reveals microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer.

TL;DR: A microfluidic device is adapted for efficient capture of CTCs from an endogenous mouse pancreatic cancer model and single-molecule RNA sequencing is subjected, identifying Wnt2 as a candidate gene enriched in C TCs, to identify candidate therapeutic targets to prevent the distal spread of cancer.

TL;DR: Microfluidic capture of circulating tumor cells (CTC) is used to measure AR signaling readouts before and after therapeutic interventions to help target treatments to patients most likely to respond to second-line therapies.

TL;DR: Cabozantinib 40 mg daily was associated with better tolerability than previously reported for cabozant inib 100 mg daily and informed the design of phase III studies of cabozaninib in mCRPC.